Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

ASLAN Pharmaceuticals Limited (ASLN)

4.195   0.005 (0.12%) 06-06 15:15
Open: 4.09 Pre. Close: 4.19
High: 4.195 Low: 4.02
Volume: 80,433 Market Cap: 69(M)

Technical analysis

as of: 2023-06-06 3:17:23 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 4.98     One year: 5.47
Support: Support1: 3.58    Support2: 2.98
Resistance: Resistance1: 4.26    Resistance2: 4.69
Pivot: 4.1
Moving Average: MA(5): 4.13     MA(20): 4.18
MA(100): 3.63     MA(250): 3.11
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 55.5     %D(3): 53.1
RSI: RSI(14): 52.2
52-week: High: 4.94  Low: 1.7
Average Vol(K): 3-Month: 53 (K)  10-Days: 95 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ASLN ] has closed below upper band by 48.9%. Bollinger Bands are 33.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.26 - 4.29 4.29 - 4.31
Low: 4 - 4.02 4.02 - 4.05
Close: 4.11 - 4.15 4.15 - 4.19

Company Description

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Headline News

Thu, 01 Jun 2023
2023-06-01 | NDAQ:ASLN | Press Release | ASLAN ... - Stockhouse Publishing

Wed, 31 May 2023
Roth MKM Initiates Coverage of ASLAN Pharmaceuticals Ltd - ADR ... - Nasdaq

Thu, 18 May 2023
ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of ... - BioSpace

Sat, 29 Apr 2023
HC Wainwright & Co. Maintains ASLAN Pharmaceuticals Ltd - ADR ... - Nasdaq

Tue, 28 Mar 2023
ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing ... - GlobeNewswire

Mon, 13 Mar 2023
Hedge funds owners may take dramatic actions as ASLAN Pharmaceuticals Limited's (NASDAQ:ASLN) recent 25% drop adds to one-year losses - Simply Wall St

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 16 (M)
Shares Float 9 (M)
% Held by Insiders 0 (%)
% Held by Institutions 25.2 (%)
Shares Short 484 (K)
Shares Short P.Month 408 (K)

Stock Financials

EPS -4.2
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.67
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -44.8
Return on Equity (ttm) -209.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.31
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.98
PEG Ratio 0
Price to Book value 6.13
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.